Comments
Pharma major Dr Reddy's Laboratories Ltd has received approval from the US Food and Drug Administration (US FDA) for ZEMBRACE SymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine in adults.
It is available as a prefilled, ready-to-use, single dose disposable auto injector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously.
“ZEMBRACESymTouch is specifically designed for patients who may experience certain migraine episodes and for whom a pill may not be the right option,’’ Raghav Chari, Executive Vice-President, Proprietary Products Group, Dr Reddy’s, said in a release issued here on Friday.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.